In ovarian cancer models, combining cystinase with immune checkpoint inhibitors, specifically PD-L1 blockers, has been shown to amplify T cell-driven anti-tumor responses, resulting in enhanced tumor suppression (Xiong et al., 2021). This evidence concerns the gene CD274 and ovarian cancer.